Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.
Who: Gilead Sciences/Merus N.V.
What: Gilead is teaming with Merus to discover and develop trispecific antibodies that the companies say would target dual tumor-associated...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.
After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
